NADH (Reduced Nicotinamide Adenine Dinucleotide) is NAD+ in its electron-carrying reduced form. It directly participates in the mitochondrial electron transport chain, where it donates electrons to drive ATP production—the body's primary energy currency.
Unlike NAD+ precursors that require enzymatic conversion, NADH targets immediate energy metabolism and cognitive function support. However, it is extremely unstable—even more so than NAD+—making liposomal encapsulation essential for viable oral supplementation.
NADH is even more unstable than NAD+—readily inactivated by exposure to light, oxygen, and gastric acid. Conventional oral NADH exhibits extremely low intestinal uptake and limited systemic entry.
Liposomal encapsulation is the technological solution that makes NADH supplementation viable:
A phospholipid bilayer vesicle engineered at nanoscale to protect NADH and deliver the active reduced coenzyme directly into cells.
Non-GMO sunflower lecithin
Double-layer membrane mimicking natural cell structure. Hydrophilic heads face outward and inward; hydrophobic tails form the core barrier.
Acid & oxidation resistant
The lipid tail core blocks gastric acid, enzymes, and oxidation. NADH — extremely sensitive to light, oxygen, and pH — stays intact through stomach transit with zero degradation.
≥98% purity reduced coenzyme I
Water-soluble NADH (the reduced, biologically active form of NAD+) encapsulated in the inner aqueous compartment. Protected from oxidation until membrane fusion releases it intracellularly.
Direct intracellular uptake
Liposome bilayer fuses with cell membrane, releasing NADH directly into the cytoplasm. Delivers the active reduced coenzyme — no enzymatic conversion required, fastest route to boosting cellular NAD+/NADH ratio.
Five-stage GMP manufacturing process ensuring uniform particle size, high encapsulation efficiency, and NADH stability.
Phospholipids dissolved in organic solvent, dried to a thin film under vacuum. NADH aqueous solution added under nitrogen protection to prevent oxidation.
Probe sonication breaks down multi-lamellar vesicles into uniform small unilamellar vesicles (SUVs), 80-200 nm. Low-temperature process to preserve NADH activity.
High-pressure homogenization at 20,000 psi ensures narrow particle size distribution (PDI < 0.2) and long-term stability.
Sterile filtration (0.22 µm), encapsulation efficiency testing (≥92%), NADH purity verification (UV 340nm), and microbial screening.
Cryoprotectant-added freeze-drying for powder or nitrogen-blanketed aseptic filling for liquid. Full COA with every batch.
Research-informed benefits of liposomal NADH for energy, cognition, and performance.
Directly participates in mitochondrial electron transport chain for ATP generation and sustained energy.
Supports brain energy metabolism and neural function for focus, memory, and mental clarity.
Supports muscle energy supply and recovery for improved physical performance.
Improves daily vitality and accelerates post-exertion recovery.
NADH excels when positioned as part of a complementary energy + longevity strategy. The most powerful product formulations pair NADH's immediate ATP-generating capability with NAD+ precursors for sustained systemic NAD+ elevation.
Key formulation routes for liposomal NADH include:
Development Tip: Stabilization (liposomal/lyophilized) is your core differentiator.
Evidence-based product development guidance for NADH formulations.
| Route | Typical Dosage | Notes |
|---|---|---|
| Oral (Liposomal) | 5–20 mg/day | Lower than NAD+ precursors |
| Combination | Paired with NR/NMN | Direct energy + sustained NAD+ |
No unified regulatory dosage. Above ranges reflect common supplement intervals. Not medical advice.
Common questions about liposomal NADH.
Request samples, review our technical documentation, or speak with a formulation specialist about integrating liposomal NAD+ into your product line.